scholarly journals Stem cell therapies for ischemic stroke: current animal models, clinical trials and biomaterials

RSC Advances ◽  
2017 ◽  
Vol 7 (30) ◽  
pp. 18668-18680 ◽  
Author(s):  
Hugh H. Chan ◽  
Connor A. Wathen ◽  
Ming Ni ◽  
Shuangmu Zhuo
Keyword(s):  
Tissue Engineering ◽  
Clinical Trials ◽  
Stem Cell ◽  
Ischemic Stroke ◽  
Animal Models ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Stem Cell Therapies ◽  
Cell Therapies

We report the facilitation of stem cell therapy in stroke by tissue engineering and applications of biomaterials.

P1662All cause mortality outcomes of various types of stem cell therapies in patients with dilated cardiomyopathy: an updated meta analysis and systematic review

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
Y Illahi ◽  
M Nadeem ◽  
M Munir Ahmad ◽  
E Fatima Tariq ◽  
J Safdar
Keyword(s):  
Clinical Trials ◽  
Stem Cell ◽  
Cell Therapy ◽  
Dilated Cardiomyopathy ◽  
Stem Cell Therapy ◽  
Standard Therapy ◽  
Therapy Group ◽  
Meta Analysis ◽  
Stem Cell Therapies ◽  
Cell Therapies

Abstract Background Dilated Cardiomyopathy (ischemic and non-ischemic) has been associated with very high mortality despite maximal medical and device therapy. Recently, several clinical trials involving different types of stem cells for the management of dilated cardiomyopathy have shown significant improvement in cardiac function, however, these studies were not powered to calculate mortality benefit. A previous meta analysis included 17 randomized controlled trials, however, there has been new randomized trials published since last meta analysis, hence the need for an updated meta analysis. Purpose Comparison of all cause mortality rate between stem cell therapy group and standard therapy group in patients with Dilated Cardiomyopathy followed for 12 months or more. Methods We conducted a systematic search of Medline (Pubmed) and Cochrane Central Register of Controlled Trials for abstracts and fully published studies (from inception through April, 2018) comparing various types of stem cell therapies with standard of therapy for patients with dilated cardiomyopathy (ischemic and non-ischemic). Study selection Only fully published randomized clinical trials and abstracts of randomized trials comparing all cause mortality outcomes of various types of stem cell therapies and standard therapy for patient with dilated cardiomyopathy (ischemic and non-ischemic) followed over a period of 12 or more months were included in our meta-analysis. Total of 1392 studies were identified. Studies which were duplicate, non-randomized, included pediatric population, systematic reviews or meta-analysis, study designs or protocols, trials including gene therapy or had follow up of patients for less than 12 months were excluded. Data extraction and Synthesis: Data were abstracted by two independent reviewers. Using Mantel-Haenszal method, a random effect model was used to calculate weighted Risk ratio (RR). RevMan 5.3 was used for statistical analyses. Results Twenty eight fully published randomized clinical trials and one abstract of randomized controlled trial met inclusion criteria of our analysis. Using Mantel-Haenszel method, a random effect model was used to calculate the weighted risk ratios. Our analysis included a total of 1662 patients. Stem cell therapy group showed significant reduction in mortality compared to standard therapy group (risk ratio [RR], 0.68; 95% confidence interval, 0.53–0.87) Fig 1. Tests for statistical heterogeneity did not show any significant heterogeneity p-value = 0.80 (I2 = 0%). Limitations of our study include selection, attrition and performance biases in the included studies. Fig 2 shows distribution of the included studies. Conclusion Stem cell therapy is associated with significant mortality reduction in patients with dilated cardiomyopathy (ischemic and non-ischemic). Our meta-analysis underscores the importance of conducting large randomized clinical trial to assess the mortality outcomes of stem cell therapy.

scholarly journals A Look into Stem Cell Therapy: Exploring the Options for Treatment of Ischemic Stroke

2017 ◽  
Vol 2017 ◽  
pp. 1-14 ◽  
Author(s):  
Cesar Reis ◽  
Michael Wilkinson ◽  
Haley Reis ◽  
Onat Akyol ◽  
Vadim Gospodarev ◽  
...  
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Stem Cell ◽  
Ischemic Stroke ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Survival Rates ◽  
Cell Types ◽  
Therapeutic Benefit ◽  
Cell Therapies

Neural stem cells (NSCs) offer a potential therapeutic benefit in the recovery from ischemic stroke. Understanding the role of endogenous neural stem and progenitor cells under normal physiological conditions aids in analyzing their effects after ischemic injury, including their impact on functional recovery and neurogenesis at the site of injury. Recent animal studies have utilized unique subsets of exogenous and endogenous stem cells as well as preconditioning with pharmacologic agents to better understand the best situation for stem cell proliferation, migration, and differentiation. These stem cell therapies provide a promising effect on stimulation of endogenous neurogenesis, neuroprotection, anti-inflammatory effects, and improved cell survival rates. Clinical trials performed using various stem cell types show promising results to their safety and effectiveness on reducing the effects of ischemic stroke in humans. Another important aspect of stem cell therapy discussed in this review is tracking endogenous and exogenous NSCs with magnetic resonance imaging. This review explores the pathophysiology of NSCs on ischemic stroke, stem cell therapy studies and their effects on neurogenesis, the most recent clinical trials, and techniques to track and monitor the progress of endogenous and exogenous stem cells.

scholarly journals Targeting Programmed Cell Death to Improve Stem Cell Therapy: Implications for Treating Diabetes and Diabetes-Related Diseases

2021 ◽  
Vol 9 ◽  
Author(s):  
Qi Zhang ◽  
Xin-xing Wan ◽  
Xi-min Hu ◽  
Wen-juan Zhao ◽  
Xiao-xia Ban ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cell Death ◽  
Stem Cell ◽  
Programmed Cell Death ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Therapeutic Effects ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Wide Range

Stem cell therapies have shown promising therapeutic effects in restoring damaged tissue and promoting functional repair in a wide range of human diseases. Generations of insulin-producing cells and pancreatic progenitors from stem cells are potential therapeutic methods for treating diabetes and diabetes-related diseases. However, accumulated evidence has demonstrated that multiple types of programmed cell death (PCD) existed in stem cells post-transplantation and compromise their therapeutic efficiency, including apoptosis, autophagy, necroptosis, pyroptosis, and ferroptosis. Understanding the molecular mechanisms in PCD during stem cell transplantation and targeting cell death signaling pathways are vital to successful stem cell therapies. In this review, we highlight the research advances in PCD mechanisms that guide the development of multiple strategies to prevent the loss of stem cells and discuss promising implications for improving stem cell therapy in diabetes and diabetes-related diseases.

scholarly journals dvances of hyaluronic acid in stem cell therapy and tissue engineering, including current clinical trials

2019 ◽  
Vol 37 ◽  
pp. 186-213 ◽  
Author(s):  
E López-Ruiz ◽  
◽  
G Jiménez ◽  
L Álvarez de Cienfuegos ◽  
C Antich ◽  
...  
Keyword(s):  
Tissue Engineering ◽  
Clinical Trials ◽  
Stem Cell ◽  
Hyaluronic Acid ◽  
Cell Therapy ◽  
Stem Cell Therapy

scholarly journals Immunological Barriers to Stem Cell Therapy in the Central Nervous System

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Gregory E. Tullis ◽  
Kathleen Spears ◽  
Mark D. Kirk
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Brain Disorders ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Cell Transplants ◽  
The Central Nervous System

The central nervous system is vulnerable to many neurodegenerative disorders such as Alzheimer’s disease that result in the extensive loss of neuronal cells. Stem cells have the ability to differentiate into many types of cells, which make them ideal for treating such disorders. Although stem cell therapy has shown some promising results in animal models for many brain disorders it has yet to translate into the clinic. A major hurdle to the translation of stem cell therapy into the clinic is the immune response faced by stem cell transplants. Here, we focus on immunological and related hurdles to stem cell therapies for central nervous system disorders.

scholarly journals Cardiomyocyte Death and Genome-Edited Stem Cell Therapy for Ischemic Heart Disease

2021 ◽  
Author(s):  
Hyun-Min Cho ◽  
Je-Yoel Cho
Keyword(s):  
Stem Cells ◽  
Cell Death ◽  
Stem Cell ◽  
Heart Disease ◽  
Cell Therapy ◽  
Ischemic Heart Disease ◽  
Genome Editing ◽  
Stem Cell Therapy ◽  
Stem Cell Therapies ◽  
Cell Therapies

AbstractMassive death of cardiomyocytes is a major feature of cardiovascular diseases. Since the regenerative capacity of cardiomyocytes is limited, the regulation of their death has been receiving great attention. The cell death of cardiomyocytes is a complex mechanism that has not yet been clarified, and it is known to appear in various forms such as apoptosis, necrosis, etc. In ischemic heart disease, the apoptosis and necrosis of cardiomyocytes appear in two types of programmed forms (intrinsic and extrinsic pathways) and they account for a large portion of cell death. To repair damaged cardiomyocytes, diverse stem cell therapies have been attempted. However, despite the many positive effects, the low engraftment and survival rates have clearly limited the application of stem cells in clinical therapy. To solve these challenges, the introduction of the desired genes in stem cells can be used to enhance their capacity and improve their therapeutic efficiency. Moreover, as genome engineering technologies have advanced significantly, safer and more stable delivery of target genes and more accurate deletion of genes have become possible, which facilitates the genetic modification of stem cells. Accordingly, stem cell therapy for damaged cardiac tissue is expected to further improve. This review describes myocardial cell death, stem cell therapy for cardiac repair, and genome-editing technologies. In addition, we introduce recent stem cell therapies that incorporate genome-editing technologies in the myocardial infarction model.

scholarly journals Stem Cell Therapy for Lower Extremity Diabetic Ulcers: Where Do We Stand?

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Mei Yang ◽  
Lingling Sheng ◽  
Tian R. Zhang ◽  
Qingfeng Li
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Science Studies ◽  
Clinical Problem ◽  
Diabetic Patients ◽  
Stem Cell Therapies ◽  
Diabetic Ulcer ◽  
Cell Therapies ◽  
Important Clinical Problem

The impairment of wound healing in diabetic patients is an important clinical problem affecting millions of patients worldwide. Various clinical and basic science studies show that stem cell therapy, as a regenerative medical therapy, can be a good solution. In this paper, we begin with an introduction of the cellular mechanism of the diabetic ulcer. We will then discuss the advantages and limitations of various stem cell therapies that have been under extensive recent study.

Bioengineering tools to elucidate and control the fate of transplanted stem cells

2014 ◽  
Vol 42 (3) ◽  
pp. 679-687 ◽  
Author(s):  
Rukmani Sridharan ◽  
Jeffrey M. Karp ◽  
Weian Zhao
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Stem Cell ◽  
Cell Therapy ◽  
Cell Fate ◽  
Stem Cell Therapy ◽  
Search Term ◽  
Cell Therapies ◽  
Cellular Microenvironments ◽  
And Control

For the last decade, stem cell therapies have demonstrated enormous potential for solving some of the most tragic illnesses, diseases and tissue defects worldwide. Currently, more than 1300 clinical trials use stem cell therapy to solve a spectrum of cardiovascular, neurodegenerative and autoimmune diseases (http://www.clinicaltrials.gov, Jan 2014, search term: stem cell therapy; only currently recruiting and completed studies are included in the search). However, the efficacy of stem cell transplantation in patients has not been well established, and recent clinical trials have produced mixed results. We attribute this lack of efficacy in part to an incomplete understanding of the fate of stem cells following transplantation and the lack of control over cell fate, especially cell-homing and therapeutic functions. In the present review, we present two of our recently developed technologies that aim to address the above-mentioned bottlenecks in stem cell therapy specifically in the areas of MSCs (mesenchymal stem cells): (i) aptamer-based cell-surface sensors to study cellular microenvironments, and (ii) mRNA engineering technology to enhance the homing and immunomodulatory efficacy of transplanted stem cells. The first engineering strategy aims to elucidate the basic cellular signalling that occurs in the microenvironment of transplanted stem cells in real time. The second technique involves a simple mRNA transfection that improves the homing and anti-inflammatory capability of MSCs. Although we have specifically applied these engineering techniques to MSCs, these strategies can be incorporated for almost any cell type to determine and control the fate of transplanted stem cells.

scholarly journals An Overview of Stem Cell Therapies for Parkinson’s Disease

2021 ◽  
Vol 2 (1) ◽  
pp. 143-158
Author(s):  
Sara Faour ◽  
Aarthi Ashok
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Stem Cell ◽  
Cell Therapy ◽  
Neurodegenerative Diseases ◽  
Stem Cell Therapy ◽  
Brain Regions ◽  
Stem Cell Therapies ◽  
Cell Therapies

Parkinson’s disease (PD) is referred to as a neurodegenerative disease which is a disease that targets specific brain regions and is characterized by neuronal death. PD is believed to be caused by the loss of nerve cells in the substantia nigra (SN), a dopamine releasing area (Dickson, 2012). Current treatments are directed at alleviating pain symptoms and slowing down the progression of disease, however, no cure currently exists. Recent advances in stem cell therapies raise new possibilities to treat neurodegenerative diseases. Stem cells have the ability to differentiate into neural cells, and thus, could potentially be used to restore neurogenesis and neuroplasticity (Lunn et al., 2011). There exist several cell types that can be applied in therapy including embryonic stem cells (ESCs), neural stem cells (NSCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs). PD which has localized neural degeneration to the SN may serve as a better model for stem cell therapy and displays greater success when compared to other neurodegenerative diseases that spread to several brain regions (Vasic et al., 2019). This review aims to discuss the several approaches used in stem cell therapy as well as the current challenges and shortcomings of this cell-based therapy.

Sign in / Sign up

Export Citation Format

Share Document